Business Context and Reporting Period
Company: GRI Bio, Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: December 8, 2025
Event: Announcement of topline data from the Phase 2a GRI-0621-IPF-02 clinical trial evaluating GRI-0621 for the treatment of Idiopathic Pulmonary Fibrosis (IPF).
Key Financial Metrics
This filing is a Current Report on Form 8-K regarding clinical trial results. It does not contain financial statements, revenue, profit, cash flow, margin, debt, or liquidity data. The filing text does not provide a clear value for any financial metrics.
Material Changes and Clinical Results
The primary material change is the successful completion of the Phase 2a trial primary endpoint (safety and tolerability) and positive secondary/exploratory data:
- Primary Endpoint: The trial met its primary endpoint of safety and tolerability over a 12-week period. No treatment-related serious adverse events were observed.
- Lung Function (FVC): Placebo-adjusted changes in Forced Vital Capacity (FVC) increased by 99 ml in the GRI-0621 arm and 139 ml in the subset taking GRI-0621 plus standard of care. A post-hoc analysis excluding outliers showed increases of 54 ml and 81 ml, respectively.
- Subject Outcomes: 39% of GRI-0621 treated subjects experienced an increase in FVC at 12 weeks, compared to 80% of placebo-treated subjects who experienced a decline.
- Biomarkers: Changes in serum biomarkers (collagen types I, III, VI, and IV) suggested an anti-fibrotic effect and the initiation of an alveolar basement membrane repair mechanism.
- Safety Profile: Adverse events were primarily Grade 2 (17%) or Grade 3 (4%), with dry skin, dry lips, and muscle/joint pain being most common. Notably, there were no increases in cough (0% vs 25% in placebo) or gastrointestinal disorders (diarrhea 13% vs 33% in placebo).
- Study Design: 35 subjects enrolled (2:1 randomization to GRI-0621 4.5mg or placebo). 80% of subjects were on background therapy (pirfenidone or nintedanib).
Guidance, Outlook, and Risks
Outlook: The Company is continuing to evaluate secondary and exploratory endpoints, including flow cytometry, RNAseq, TCRseq, and pharmacodynamic activity. The data supports the potential for GRI-0621 to resolve fibrosis and repair lung tissue.
Risks and Contingencies: The filing includes standard forward-looking statement disclaimers. Key risks identified include:
- Inability to maintain Nasdaq Capital Market listing.
- Inability to raise future financing.
- Uncertainty regarding the success, cost, and timing of future product development.
- Regulatory clearance or approval risks.
- Competition and market size uncertainties.
- Intellectual property protection challenges.
Investor Verification Checklist
- Verify the full clinical study report for detailed statistical analysis of the FVC data, particularly the methodology for the post-hoc outlier exclusion.
- Confirm the timeline for the release of the remaining secondary and exploratory endpoint data (flow cytometry, RNAseq, TCRseq).
- Review the Company's most recent Form 10-K (filed March 14, 2025) for current cash runway and financing needs, as this 8-K does not provide financial status.
- Assess the Company's ability to maintain Nasdaq listing requirements given its pre-revenue status and reliance on future financing.
- Monitor regulatory discussions regarding the next phase of clinical development for GRI-0621.